Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Transforming growth factor-β (TGFβ) promotes tumor growth through intrinsic and extrinsic pathways.
• Targeting the TGFβ pathway is a promising strategy for cancer therapeutics.

Purpose of the Study:

• To characterize the anti-tumor activity of galunisertib, a small molecule inhibitor of TGFβ receptor I (TGFβRI).
• To establish a pharmacokinetic/pharmacodynamic profile and understand the mechanism of action of galunisertib in preclinical cancer models.

Main Methods:

• Utilized preclinical models to assess galunisertib's inhibition of TGFβRI and downstream SMAD phosphorylation (pSMAD).
• Evaluated galunisertib's anti-tumor effects, including inhibition of cell migration, mesenchymal phenotype, and immune suppression.
• Established a concentration-effect relationship and dosing schedule for optimal target modulation.
• Correlated pSMAD inhibition in tumor tissues and peripheral blood mononuclear cells (PBMCs) in a rat model.

Main Results:

• Galunisertib demonstrated potent and selective inhibition of TGFβRI and downstream pSMAD signaling.
• Observed significant anti-tumor activity, including reduced tumor cell migration, reversal of immune suppression, and tumor growth delay.
• Established a dosing schedule for optimal target modulation.
• Validated PBMCs as a viable surrogate for monitoring pharmacodynamic effects of galunisertib.

Conclusions:

• Galunisertib effectively inhibits TGFβ-dependent functions, leading to anti-tumor activity in preclinical models.
• The study provides a strong rationale for the continued clinical development of galunisertib and other TGFβ pathway inhibitors in cancer therapy.